Scientists Identify microRNA Signatures That Predict Stem Cell Therapy Response in Knee Osteoarthritis
核心洞察
A long-term follow-up of a Health Canada-authorized phase I/IIa trial found that six of twelve knee osteoarthritis (搜索) patients were responders to autologous bone marrow-derived MSC injections at 12 months, with benefits sustained at 24 months.
MSCs from responders demonstrated greater anti-inflammatory effects and dampened immune cell reactivity more effectively than MSCs from non-responders in lab-based tests.
Researchers identified 14 microRNAs present at different levels in responder versus non-responder MSCs, suggesting a potential biomarker panel for predicting MSC potency.
Knee osteoarthritis (搜索) (KOA) affects more than one in ten people over 40 years of age, impairing mobility and quality of life. Despite the growing popularity of stem cell injections as a treatment option, clinical trials have yielded inconsistent results, with no clear consensus on efficacy. Now, researchers from the Schroeder Arthritis Institute (搜索) at the University Health Network in Canada have identified key biological differences in mesenchymal stromal cells (MSCs) that may explain why some patients benefit from stem cell therapy while others do not — and how to predict potency before treatment.
The findings, published in Stem Cell Reports, come from a long-term follow-up to a Health Canada-authorized phase I/IIa clinical trial (NCT02351011) in which KOA patients received injections of MSCs derived from their own bone marrow.
Responder classification reveals durable benefit in half of patients
Led by Sowmya Viswanathan, the research team tracked patient-reported pain and mobility scores over 24 months. Patients reporting at least 20% improvement in both pain and knee mobility were classified as responders, while non-responders showed no improvement or worsening in these measures.
At the 12-month follow-up, six out of twelve patients met the responder criteria. Importantly, the majority of these responders maintained their improvements through the 24-month assessment, suggesting durable therapeutic benefit in a subset of patients.
Lab-based assays uncover functional differences in MSCs
To investigate what distinguished responders from non-responders, Viswanathan's team conducted a panel of laboratory tests on the MSCs from all 12 trial participants. The results revealed clear functional differences: MSCs from responders exhibited a greater anti-inflammatory effect and dampened immune cell reactivity more effectively than MSCs from non-responders.
Further molecular analysis identified 14 microRNAs — short RNAs that regulate gene expression — present in significantly different quantities between responder and non-responder MSCs. These microRNAs may serve as a predictive signature for MSC therapeutic potency.
Notably, baseline values for disease severity and inflammation did not correlate with therapy response, indicating that cell-intrinsic features, rather than patient baseline characteristics, drive treatment outcomes.
Toward personalized stem cell therapy for KOA
The study suggests that lab-based screening of cultured MSCs could enable clinicians to pre-select only those cells with enhanced therapeutic potential for clinical application. Such an approach could reduce the heterogeneity that has plagued MSC trials in osteoarthritis and improve consistency of outcomes.
"Predicting MSC potency could be a powerful tool to achieve more consistent therapeutic outcomes in such therapeutic settings," the authors note. However, the researchers emphasize that follow-up controlled clinical studies with larger patient cohorts will be required to corroborate these findings before such predictive tests can enter routine clinical use.
The work addresses a critical gap in the field, where stem cell injections have been widely promoted despite limited evidence of efficacy from rigorous clinical trials and where variability in cell quality between patients has contributed to inconsistent results.